Search

Search Results

• SGLT2 inhibitors and risk reduction for mortality in high-risk patients: a meta-analysis of randomized controlled trials

  Tariq Jamal Siddiqi, Javed Butler, Andrew J.S. Coats, Subodh Verma, Tim Friede, Gerasimos Filippatos, Stefan D. Anker

  2023-11-23

  https://doi.org/10.4081/cardio.2023.2

  1548

  pdf: 416

  Supplementary Material: 100

  HTML: 236

• Effect of metformin and empagliflozin on myocardial function in insulin-resistant patients with heart failure: rationale and design of the METRIS-HF-DZHK18 Trial

  Wolfram Doehner, Tim Friede, Frank Edelmann, Ulf Landmesser, Sebastian Winkler, Burkert Pieske, Fabian Knebel, Sebastian Kelle, Diethelm Tschöpe, Antje Meyer, Nadja Jauert, Marius Placzek, Jeanette Schulz-Menger, Stephan von Haehling, Stefan D. Anker

  2025-12-31

  https://doi.org/10.4081/cardio.2025.89

  529

  PDF: 278

  Appendix: 79

  HTML: 20

• Optimized heart failure therapy in patients with very advanced cancer in palliative care: dosing strategies from the EMPATICC trial

  Markus S. Anker, Sven Bercker, Ulrich Laufs, Michael Böhm, Bela Merkely, Monika Diek, Tim Heise, Martin Hellmich, Marius Placzek, Tim Friede, Stefan D. Anker, Lorenz Lehmann, Ulf Landmesser, Dominik P. Modest, Muhammad Shahzeb Khan, Amir A. Mahabadi, Matthias Totzeck, Mitra Tewes, Muhammad Sameer Arshad, Raluca Mincu, Javed Butler, Ulrich Keller, Johann Ahn, Lars Bullinger, Tienush Rassaf

  2025-08-20

  https://doi.org/10.4081/cardio.2025.78

  804

  PDF: 558

  Appendix: 299

  HTML: 79

• The effect of SGLT2 inhibitors on health status in patients with heart failure: a systematic review and meta-analysis

  Muhammad Shariq Usman, Arsalan Hamid, Shurjeel Uddin Qazi, Mikhail N. Kosiborod, Deepak L. Bhatt, Muhammad Shahzeb Khan, Muthiah Vaduganathan, Javed Butler

  2024-06-28

  https://doi.org/10.4081/cardio.2024.35

  3791

  PDF: 896

  Conflict of interest: 388

  SUPPLEMENTARY MATERIAL: 341

  HTML: 123

• Iron deficiency in heart failure with preserved ejection fraction: rationale and design of the FAIR-HFpEF trial

  Stephan von Haehling, Wolfram Doehner, Ruben Evertz, Tania Garfias-Veitl, Monika Diek, Mahir Karakas, Ralf Birkemeyer, Gerasimos Fillippatos, Piotr Ponikowski, Michael Böhm, Tim Friede, Stefan D. Anker

  2023-12-27

  https://doi.org/10.4081/cardio.2023.15

  3007

  pdf: 917

  HTML: 69

• Aldosterone synthase inhibitors in cardio-renal diseases: a state-of-the-art review

  Muhammad Hamza Dawood, Muhammad Shahzeb Khan, Ahmed Mustafa Rashid, Wilhelm Haverkamp

  2025-12-31

  https://doi.org/10.4081/cardio.2025.91

  1051

  PDF: 670

  HTML: 125

• Beyond trial neutrality: treatment discontinuation and the hidden signal in SPIRIT-HF trial

  Viana Copeland, Andrew J.S. Coats

  2026-03-31

  https://doi.org/10.4081/cardio.2026.100

  1467

  PDF: 425

  HTML: 245

• Using multiple primary endpoints in clinical trials with a focus on heart failure

  Stefan D. Anker, Javed Butler, Khawaja M. Talha, Tim Friede

  2024-06-28

  https://doi.org/10.4081/cardio.2024.33

  6528

  PDF: 987

  HTML: 422

• Treatment pathways in patients with heart failure with preserved ejection fraction and obesity: perspectives from cardiology specialists and patients

  Javed Butler, Sanjiv J. Shah, Melissa Magwire, Carlos Campos, Muhammad Shariq Usman, Anthony Hoovler, Anup Sabharwal, Barry A. Borlaug

  2024-06-28

  https://doi.org/10.4081/cardio.2024.38

  2531

  PDF: 1173

  SUPPLEMENTARY MATERIAL: 396

  GRAPHICAL ABSTRACT: 326

  HTML: 215

• Dyslipidemia and stroke-related mortality in the United States: a nationwide analysis for 2010-2020

  Muhammad Muneeb Ur Rehman, Iliyan Mithani, Muhammad Sameer Arshad, Syed Raza Shah, Wolfram Doehner, Anandita Kulkarni

  2025-12-31

  https://doi.org/10.4081/cardio.2025.90

  548

  PDF: 225

  Supplementary: 78

  HTML: 92

• Obesity and left atrial function: state of the art

  Ahmed Mustafa Rashid, Muhammad Shahzeb Khan, Fawaz Alenezi, Stefan D. Anker, Fabian Knebel

  2026-03-31

  https://doi.org/10.4081/cardio.2026.96

  1038

  PDF: 370

  HTML: 147

• Relaxin-2 for heart failure with preserved ejection fraction: a comment on the termination of a phase-II trial investigating the relaxin-2 analogue, LY3540378

  Thomas Bernd Dschietzig, Guy Salama

  2024-12-30

  https://doi.org/10.4081/cardio.2024.56

  5073

  PDF: 1055

  HTML: 136

• Metabolic dysfunction-associated steatotic liver disease and cardiovascular disease: a state-of-the-art review

  Aimen Shafiq, Ahmed Mustafa Rashid, Syed Raza Shah, Nicholas W.S. Chew, Wilhelm Haverkamp

  2026-04-10

  https://doi.org/10.4081/cardio.2026.94

  4214

  PDF: 1595

  HTML: 340